Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1233 EUR
−20.34 M EUR
1.80 M EUR
133.56 M
About VALERIO THERAPEUTICS
Sector
CEO
Julien Miara
Headquarters
Paris
Website
Founded
1997
ISIN
FR0010095596
FIGI
BBG000HQ55Z8
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The firm produces and develops orphan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Jean Theron, Gilles Avenard, and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALVIO is 0.0720 EUR — it has increased by 1.11% in the past 24 hours. Watch VALERIO THERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange VALERIO THERAPEUTICS stocks are traded under the ticker ALVIO.
ALVIO stock has fallen by −9.00% compared to the previous week, the month change is a −14.35% fall, over the last year VALERIO THERAPEUTICS has showed a −59.09% decrease.
ALVIO reached its all-time high on Sep 23, 2014 with the price of 7.9279 EUR, and its all-time low was 0.0650 EUR and was reached on Aug 20, 2024. View more price dynamics on ALVIO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALVIO stock is 5.42% volatile and has beta coefficient of −0.04. Track VALERIO THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is VALERIO THERAPEUTICS there?
Today VALERIO THERAPEUTICS has the market capitalization of 11.21 M, it has decreased by −9.00% over the last week.
Yes, you can track VALERIO THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
VALERIO THERAPEUTICS is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ALVIO net income for the last half-year is −10.96 M EUR, while the previous report showed −8.70 M EUR of net income which accounts for −25.95% change. Track more VALERIO THERAPEUTICS financial stats to get the full picture.
No, ALVIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VALERIO THERAPEUTICS EBITDA is −18.55 M EUR, and current EBITDA margin is −1.16 K%. See more stats in VALERIO THERAPEUTICS financial statements.
Like other stocks, ALVIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VALERIO THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VALERIO THERAPEUTICS technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VALERIO THERAPEUTICS stock shows the sell signal. See more of VALERIO THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.